Austedo, manufactured by Teva Pharmaceuticals, is a medication used to treat chorea associated with Huntington's disease and tardive dyskinesia [1]. The AUSTEDO titration pack is designed to facilitate a gradual increase in dosage for patients starting the medication [2].
What is the NDC for the Austedo Titration Pack?
The National Drug Code (NDC) for the Austedo titration pack is 0077-2176-20 [2]. This NDC identifies a specific product configuration for the titration pack, which typically contains multiple strengths of the drug to allow for a stepped dosage increase [2].
How does the Austedo Titration Pack work?
The titration pack allows prescribers to start patients on a lower dose of Austedo and then systematically increase it over a period of weeks [2]. This approach is intended to help patients tolerate the medication better and minimize potential side effects as their bodies adjust to the drug [3]. The pack usually contains blister cards for several weeks of treatment, with each week's dosage clearly labeled [2].
What are the approved uses for Austedo?
Austedo is approved by the U.S. Food and Drug Administration (FDA) for two main conditions: chorea associated with Huntington's disease and tardive dyskinesia [1]. Huntington's disease is a progressive neurodegenerative disorder, while tardive dyskinesia is a movement disorder characterized by involuntary, repetitive movements [1][4].
When does Austedo's patent expire?
Information regarding the patent expiry for Austedo is available through resources like DrugPatentWatch.com [5]. Patent exclusivity periods are critical for determining when generic versions of a drug may become available [5].
Who manufactures Austedo?
Teva Pharmaceuticals is the manufacturer of Austedo [1].